DIEBOLD NIXDORF INC (DBD) Stock Fundamental Analysis

USA • New York Stock Exchange • NYSE:DBD • US2536512021

72.4 USD
+0.59 (+0.82%)
Last: Feb 9, 2026, 12:47 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

4

We assign a fundamental rating of 4 out of 10 to DBD. DBD was compared to 35 industry peers in the Technology Hardware, Storage & Peripherals industry. DBD has an average financial health and profitability rating. DBD has a correct valuation and a medium growth rate.


Dividend Valuation Growth Profitability Health

5

1. Profitability

1.1 Basic Checks

  • DBD had positive earnings in the past year.
  • DBD had a positive operating cash flow in the past year.
  • DBD had negative earnings in 4 of the past 5 years.
  • In multiple years DBD reported negative operating cash flow during the last 5 years.
DBD Yearly Net Income VS EBIT VS OCF VS FCFDBD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M -500M 1B

1.2 Ratios

  • DBD has a better Return On Assets (1.36%) than 68.57% of its industry peers.
  • DBD has a Return On Equity of 4.57%. This is in the better half of the industry: DBD outperforms 77.14% of its industry peers.
  • The Return On Invested Capital of DBD (8.85%) is better than 71.43% of its industry peers.
  • DBD had an Average Return On Invested Capital over the past 3 years of 5.12%. This is significantly below the industry average of 16.39%.
  • The last Return On Invested Capital (8.85%) for DBD is above the 3 year average (5.12%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 1.36%
ROE 4.57%
ROIC 8.85%
ROA(3y)4.54%
ROA(5y)0.8%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)5.12%
ROIC(5y)5.58%
DBD Yearly ROA, ROE, ROICDBD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100 200 300

1.3 Margins

  • With a decent Profit Margin value of 1.37%, DBD is doing good in the industry, outperforming 68.57% of the companies in the same industry.
  • With a decent Operating Margin value of 7.47%, DBD is doing good in the industry, outperforming 80.00% of the companies in the same industry.
  • DBD's Operating Margin has improved in the last couple of years.
  • Looking at the Gross Margin, with a value of 25.48%, DBD is in line with its industry, outperforming 42.86% of the companies in the same industry.
  • In the last couple of years the Gross Margin of DBD has remained more or less at the same level.
Industry RankSector Rank
OM 7.47%
PM (TTM) 1.37%
GM 25.48%
OM growth 3Y20.78%
OM growth 5Y40.66%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.32%
GM growth 5Y0.68%
DBD Yearly Profit, Operating, Gross MarginsDBD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 -10 20 30

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. Health

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so DBD is destroying value.
  • DBD has about the same amout of shares outstanding than it did 1 year ago.
  • DBD has less shares outstanding than it did 5 years ago.
  • Compared to 1 year ago, DBD has an improved debt to assets ratio.
DBD Yearly Shares OutstandingDBD Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
DBD Yearly Total Debt VS Total AssetsDBD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B 4B 5B

2.2 Solvency

  • DBD has an Altman-Z score of 1.99. This is not the best score and indicates that DBD is in the grey zone with still only limited risk for bankruptcy at the moment.
  • DBD has a Altman-Z score of 1.99. This is in the better half of the industry: DBD outperforms 62.86% of its industry peers.
  • DBD has a debt to FCF ratio of 3.71. This is a good value and a sign of high solvency as DBD would need 3.71 years to pay back of all of its debts.
  • DBD's Debt to FCF ratio of 3.71 is fine compared to the rest of the industry. DBD outperforms 68.57% of its industry peers.
  • DBD has a Debt/Equity ratio of 0.84. This is a neutral value indicating DBD is somewhat dependend on debt financing.
  • The Debt to Equity ratio of DBD (0.84) is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.84
Debt/FCF 3.71
Altman-Z 1.99
ROIC/WACC0.94
WACC9.41%
DBD Yearly LT Debt VS Equity VS FCFDBD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1B -1B 2B

2.3 Liquidity

  • A Current Ratio of 1.36 indicates that DBD should not have too much problems paying its short term obligations.
  • DBD's Current ratio of 1.36 is in line compared to the rest of the industry. DBD outperforms 51.43% of its industry peers.
  • A Quick Ratio of 0.89 indicates that DBD may have some problems paying its short term obligations.
  • The Quick ratio of DBD (0.89) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 1.36
Quick Ratio 0.89
DBD Yearly Current Assets VS Current LiabilitesDBD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B 2.5B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. Growth

3.1 Past

  • The earnings per share for DBD have decreased strongly by -38.07% in the last year.
  • The Earnings Per Share has been growing by 69.69% on average over the past years. This is a very strong growth
  • The Revenue has decreased by -2.86% in the past year.
  • The Revenue has been decreasing by -3.18% on average over the past years.
EPS 1Y (TTM)-38.07%
EPS 3Y69.69%
EPS 5YN/A
EPS Q2Q%150.91%
Revenue 1Y (TTM)-2.86%
Revenue growth 3Y-1.33%
Revenue growth 5Y-3.18%
Sales Q2Q%1.95%

3.2 Future

  • Based on estimates for the next years, DBD will show a quite strong growth in Earnings Per Share. The EPS will grow by 19.21% on average per year.
  • The Revenue is expected to grow by 2.51% on average over the next years.
EPS Next Y8.85%
EPS Next 2Y12.85%
EPS Next 3Y19.21%
EPS Next 5YN/A
Revenue Next Year1.72%
Revenue Next 2Y1.93%
Revenue Next 3Y2.51%
Revenue Next 5YN/A

3.3 Evolution

  • Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
DBD Yearly Revenue VS EstimatesDBD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 1B 2B 3B 4B
DBD Yearly EPS VS EstimatesDBD Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 2 -2 4 6

More info and screens

Find the best growth stocksShow best growing peers

5

4. Valuation

4.1 Price/Earnings Ratio

  • DBD is valuated rather expensively with a Price/Earnings ratio of 19.78.
  • Based on the Price/Earnings ratio, DBD is valued a bit cheaper than 74.29% of the companies in the same industry.
  • DBD is valuated rather cheaply when we compare the Price/Earnings ratio to 27.93, which is the current average of the S&P500 Index.
  • Based on the Price/Forward Earnings ratio of 14.73, the valuation of DBD can be described as correct.
  • 68.57% of the companies in the same industry are more expensive than DBD, based on the Price/Forward Earnings ratio.
  • DBD is valuated rather cheaply when we compare the Price/Forward Earnings ratio to 27.77, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 19.78
Fwd PE 14.73
DBD Price Earnings VS Forward Price EarningsDBD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 5 10 15 20 25

4.2 Price Multiples

  • 94.29% of the companies in the same industry are more expensive than DBD, based on the Enterprise Value to EBITDA ratio.
  • 80.00% of the companies in the same industry are more expensive than DBD, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 10.32
EV/EBITDA 7.87
DBD Per share dataDBD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 20 40 60 80 100

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
  • DBD's earnings are expected to grow with 19.21% in the coming years. This may justify a more expensive valuation.
PEG (NY)2.24
PEG (5Y)N/A
EPS Next 2Y12.85%
EPS Next 3Y19.21%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for DBD!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

DIEBOLD NIXDORF INC

NYSE:DBD (2/9/2026, 12:47:03 PM)

72.4

+0.59 (+0.82%)

Chartmill FA Rating
GICS IndustryGroupTechnology Hardware & Equipment
GICS IndustryTechnology Hardware, Storage & Peripherals
Earnings (Last)11-05
Earnings (Next)02-12
Inst Owners105.4%
Inst Owner Change-1.5%
Ins Owners1.81%
Ins Owner Change-0.17%
Market Cap2.60B
Revenue(TTM)3.69B
Net Income(TTM)50.60M
Analysts82.86
Price Target80.58 (11.3%)
Short Float %2.32%
Short Ratio3.79
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)52.97%
Min EPS beat(2)46.39%
Max EPS beat(2)59.55%
EPS beat(4)3
Avg EPS beat(4)24.69%
Min EPS beat(4)-8.92%
Max EPS beat(4)59.55%
EPS beat(8)6
Avg EPS beat(8)71.52%
EPS beat(12)8
Avg EPS beat(12)-72.18%
EPS beat(16)9
Avg EPS beat(16)-86.09%
Revenue beat(2)1
Avg Revenue beat(2)1.41%
Min Revenue beat(2)-0.2%
Max Revenue beat(2)3.02%
Revenue beat(4)1
Avg Revenue beat(4)0.15%
Min Revenue beat(4)-1.34%
Max Revenue beat(4)3.02%
Revenue beat(8)4
Avg Revenue beat(8)0.31%
Revenue beat(12)4
Avg Revenue beat(12)-0.58%
Revenue beat(16)4
Avg Revenue beat(16)-1.83%
PT rev (1m)0%
PT rev (3m)4.41%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0.83%
EPS NY rev (1m)0%
EPS NY rev (3m)13.35%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.36%
Valuation
Industry RankSector Rank
PE 19.78
Fwd PE 14.73
P/S 0.7
P/FCF 10.32
P/OCF 9.29
P/B 2.35
P/tB N/A
EV/EBITDA 7.87
EPS(TTM)3.66
EY5.06%
EPS(NY)4.92
Fwd EY6.79%
FCF(TTM)7.01
FCFY9.69%
OCF(TTM)7.79
OCFY10.76%
SpS102.88
BVpS30.87
TBVpS-9.56
PEG (NY)2.24
PEG (5Y)N/A
Graham Number50.42
Profitability
Industry RankSector Rank
ROA 1.36%
ROE 4.57%
ROCE 11.2%
ROIC 8.85%
ROICexc 9.91%
ROICexgc 29.15%
OM 7.47%
PM (TTM) 1.37%
GM 25.48%
FCFM 6.82%
ROA(3y)4.54%
ROA(5y)0.8%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)5.12%
ROIC(5y)5.58%
ROICexc(3y)6.13%
ROICexc(5y)6.88%
ROICexgc(3y)21.8%
ROICexgc(5y)29.05%
ROCE(3y)6.48%
ROCE(5y)7.06%
ROICexgc growth 3Y-11.73%
ROICexgc growth 5Y37.89%
ROICexc growth 3Y4.77%
ROICexc growth 5Y35.34%
OM growth 3Y20.78%
OM growth 5Y40.66%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.32%
GM growth 5Y0.68%
F-Score7
Asset Turnover0.99
Health
Industry RankSector Rank
Debt/Equity 0.84
Debt/FCF 3.71
Debt/EBITDA 2.28
Cap/Depr 20.59%
Cap/Sales 0.75%
Interest Coverage 2.89
Cash Conversion 68.06%
Profit Quality 497.23%
Current Ratio 1.36
Quick Ratio 0.89
Altman-Z 1.99
F-Score7
WACC9.41%
ROIC/WACC0.94
Cap/Depr(3y)16.93%
Cap/Depr(5y)15.92%
Cap/Sales(3y)0.61%
Cap/Sales(5y)0.61%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-38.07%
EPS 3Y69.69%
EPS 5YN/A
EPS Q2Q%150.91%
EPS Next Y8.85%
EPS Next 2Y12.85%
EPS Next 3Y19.21%
EPS Next 5YN/A
Revenue 1Y (TTM)-2.86%
Revenue growth 3Y-1.33%
Revenue growth 5Y-3.18%
Sales Q2Q%1.95%
Revenue Next Year1.72%
Revenue Next 2Y1.93%
Revenue Next 3Y2.51%
Revenue Next 5YN/A
EBIT growth 1Y-5.55%
EBIT growth 3Y19.17%
EBIT growth 5Y36.19%
EBIT Next Year24.55%
EBIT Next 3Y14.01%
EBIT Next 5YN/A
FCF growth 1Y171.3%
FCF growth 3Y8.67%
FCF growth 5Y113.09%
OCF growth 1Y186.31%
OCF growth 3Y6.68%
OCF growth 5Y26.59%

DIEBOLD NIXDORF INC / DBD FAQ

What is the fundamental rating for DBD stock?

ChartMill assigns a fundamental rating of 4 / 10 to DBD.


Can you provide the valuation status for DIEBOLD NIXDORF INC?

ChartMill assigns a valuation rating of 5 / 10 to DIEBOLD NIXDORF INC (DBD). This can be considered as Fairly Valued.


What is the profitability of DBD stock?

DIEBOLD NIXDORF INC (DBD) has a profitability rating of 5 / 10.


What is the financial health of DIEBOLD NIXDORF INC (DBD) stock?

The financial health rating of DIEBOLD NIXDORF INC (DBD) is 5 / 10.


How sustainable is the dividend of DIEBOLD NIXDORF INC (DBD) stock?

The dividend rating of DIEBOLD NIXDORF INC (DBD) is 0 / 10 and the dividend payout ratio is 0%.